ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,142.00
-0.13%
S&P ASX All Technology
3,417.00
0.40%
Brent Oil
74.635
1.22%
US Dollar vs AUD
1.45285
-0.71%
Bitcoin
63,804.37
0.75%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Exscientia PLC (EXAI)

  7. Exscientia PLC (EXAI) News

EXAI

Exscientia (EXAI)

Exscientia PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:EXAI
DateTimeSourceHeadlineSymbolCompany
30/08/202422:57Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:EXAIExscientia PLC
29/08/202406:42Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EXAIExscientia PLC
29/08/202402:11Business WireExscientia wird auf der 22nd Annual Global Healthcare Conference Präsentation durchführenNASDAQ:EXAIExscientia PLC
29/08/202402:11Business WireExscientia participera à la 22e conférence annuelle de Morgan Stanley sur les soins médicaux dans le mondeNASDAQ:EXAIExscientia PLC
28/08/202421:00Business WireExscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:EXAIExscientia PLC
24/08/202406:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXAIExscientia PLC
15/08/202421:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EXAIExscientia PLC
15/08/202421:00Business WireExscientia Business Update for Second Quarter and First Half 2024NASDAQ:EXAIExscientia PLC
09/08/202419:44IH Market NewsTSMC July Revenue Surges 45%, Nasdaq Accelerates Penny Stock Delistings, Moody’s Downgrades Intel to BAA1, and MoreNASDAQ:EXAIExscientia PLC
09/08/202407:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EXAIExscientia PLC
08/08/202421:39GlobeNewswire Inc.Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End CapabilitiesNASDAQ:EXAIExscientia PLC
25/07/202406:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EXAIExscientia PLC
19/07/202402:36Business WireExscientia erwirbt volle Rechte an potenziellem CDK7-Inhibitor der Spitzenklasse vor der Veröffentlichung von Phase-1-Dosis-EskalationsdatenNASDAQ:EXAIExscientia PLC
19/07/202400:20Business WireExscientia acquiert les droits complets d’un inhibiteur potentiel de CDK7, le meilleur de sa catégorie, avant la publication des données de dose croissante de phase 1NASDAQ:EXAIExscientia PLC
18/07/202421:24Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EXAIExscientia PLC
18/07/202421:00Business WireExscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data ReadoutNASDAQ:EXAIExscientia PLC
11/07/202407:44Business WireExscientia lance une plateforme AWS optimisée par l'IA pour promouvoir la découverte de médicamentsNASDAQ:EXAIExscientia PLC
11/07/202405:13Business WireExscientia bringt KI-gestützte AWS-Plattform zur Verbesserung der Arzneimittelforschung auf den MarktNASDAQ:EXAIExscientia PLC
10/07/202421:00Business WireExscientia Launches AWS AI-powered Platform to Advance Drug DiscoveryNASDAQ:EXAIExscientia PLC
25/06/202419:45PR Newswire (US)EXAI LAWSUIT ALERT: The Gross Law Firm Notifies Exscientia plc Investors of a Class Action Lawsuit and Upcoming DeadlineNASDAQ:EXAIExscientia PLC
20/06/202419:45PR Newswire (US)Exscientia plc Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before June 25, 2024 to Discuss Your Rights - EXAINASDAQ:EXAIExscientia PLC
17/06/202419:45PR Newswire (US)Shareholders that lost money on Exscientia plc(EXAI) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreNASDAQ:EXAIExscientia PLC
10/06/202419:45PR Newswire (US)June 25, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against EXAINASDAQ:EXAIExscientia PLC
07/06/202406:16Business WireExscientia ernennt neue Führungskräfte zur Stärkung der Auswirkungen integrierter Technologien und um den Schwerpunkt auf klinische Entwicklungskompetenz in der Onkologie zu richtenNASDAQ:EXAIExscientia PLC
07/06/202406:12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EXAIExscientia PLC
07/06/202405:49Business WireExscientia nomme de nouveaux dirigeants pour accentuer l'impact des technologies intégrées et recentrer l'expertise en développement clinique sur l'oncologieNASDAQ:EXAIExscientia PLC
06/06/202421:00Business WireExscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in OncologyNASDAQ:EXAIExscientia PLC
05/06/202419:45PR Newswire (US)Shareholders that lost money on Exscientia plc(EXAI) should contact The Gross Law Firm about pending Class Action - EXAINASDAQ:EXAIExscientia PLC
31/05/202404:30Business WireExscientia participera à des conférences d'investisseurs au mois de juinNASDAQ:EXAIExscientia PLC
31/05/202403:58Business WireExscientia präsentiert sich auf kommenden Investorenkonferenzen im JuniNASDAQ:EXAIExscientia PLC
 Showing the most relevant articles for your search:NASDAQ:EXAI

Your Recent History

USOTC
HWDJY
Howden Joinery (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved